Article

Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA

Sanofi Pasteur Inc., Route 611, Discovery Drive, Swiftwater, PA 18370-0187, USA. Electronic address: .
Vaccine (Impact Factor: 3.62). 09/2013; 31(44). DOI: 10.1016/j.vaccine.2013.08.088
Source: PubMed

ABSTRACT

A candidate recombinant, live-attenuated, CYD tetravalent dengue vaccine (CYD-TDV) has recently demonstrated immunogenicity, efficacy and good tolerability. This study was performed to evaluate three CYD-TDV formulations in adults.
This was a randomized, double-blind, multicenter, phase II trial. The vaccine formulations were: CYD-TDV 5555 (≈5log10 tissue culture infectious dose 50% [TCID50] of serotypes 1-4); CYD-TDV 5553 (≈5log10 TCID50 of serotypes 1-3 and ≈3log10 TCID50 of serotype 4); and CYD-TDV 4444 (≈4log10 TCID50 of serotypes 1-4). Vaccinations were administered at 0, 6 and 12 months. Immunogenicity was assessed using the plaque reduction neutralization test.
In total, 260 individuals were enrolled. The 5555 formulation elicited a superior serotype 4 response versus the 5553 formulation, with seropositivity rates of 89.7% and 58.3%, respectively, after the second dose (between-group difference 31.4%; 95% confidence interval 18.2-43.2). After each of the three doses, seropositivity rates for serotypes 1-3 were numerically highest with CYD-TDV 5553 and lowest with the 4444 formulation; seropositivity rates for serotype 4 were similar with the 5555 and 4444 formulations, and much lower among recipients of CYD-TDV 5553. Geometric mean titers followed the same pattern as that seen with seropositivity rates. Safety/reactogenicity results were similar for all three vaccine formulations, although the percentage of participants reporting solicited injection site reactions was lower with CYD-TDV 4444 than with the other two formulations. All serious adverse events were unrelated to vaccination.
Reducing the dose of serotype 4 antigen (5553 formulation) creates an imbalance in the immune response to CYD-TDV. Immune responses to CYD-TDV 5555 were slightly higher than to the 4444 formulation. Development of CYD-TDV 5555 has subsequently been pursued.

2 Followers
 · 
29 Reads
  • Source
    • "Other locations of Wolbachia within the insect host include salivary glands and the brain, which may be correlated with reduced DENV transmission and replication [45]. The first observed pathology of Wolbachia in Aedes is that the bacteria induced restrictions on the reproduction process in infected female mosquitoes by changing their reproduction cycle and life-span, thus reducing their ability to produce progeny [48]. Wolbachia will modulate high iron level in the mosquito during blood meals, especially within the ovaries, thus disrupting the mosquito's reproduction cycle [45]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: With the increased prevalence of dengue infection in tropical countries, concerned members of the public are now pressing their local health ministries to act immediately and effectively in managing the rising numbers of reported cases. This includes reviews of the methodologies and the effectiveness of current combative systems to find other possible novel approaches that might yield better results. One of those novel approaches is the integration of a parasite into mosquito vector, manipulating the parasite-host interaction to reduce the transmission of dengue in endemic hotspots. Another alternative is by Sanofi-Pasteur’s dengue vaccine that showed over 60.8% success rate in reducing severe dengue infection in children aged 9 - 16 during its final clinical implementation phase. This report will compare and contrast these two novel ideas to determine which of the approaches are more likely to be effective in the long run. The aspects covered will include the application, effectiveness, functionality, and problems with these approaches. The results could then be utilised by governments or organizations to select precise and effective methods in reducing the prevalence of dengue infections in their countries.
    Full-text · Article · Jan 2016 · Health
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunogenicity and safety of a recombinant, live-attenuated, tetravalent dengue disease vaccine (CYD-TDV) was evaluated in children/adolescents in Brazil. In this observer-blind, placebo-controlled, phase II single-center study, children/adolescents (ages 9-16 years) were randomized to receive CYD-TDV or placebo at 0, 6, and 12 months. Immunogenicity was assessed using a 50% plaque neutralization test. Overall, 150 participants were enrolled (CYD-TDV: N = 100; placebo: N = 50). Injection site pain and headache were the most common solicited injection site and systemic reactions. Unsolicited adverse events (AEs) and serious AEs were similar between groups. No serious AEs were vaccine-related. Geometric mean titers against all dengue virus serotypes increased with CYD-TDV vaccination and were 267, 544, 741, and 432 1/dil for serotypes 1-4, respectively, after dose 3, representing a mean fold increase from baseline of 5, 6, 6, and 20, respectively. CYD-TDV vaccination elicited a neutralizing antibody response against serotypes 1-4 and was well-tolerated in children/adolescents in a dengue-endemic region.
    Full-text · Article · Nov 2013 · The American journal of tropical medicine and hygiene
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The live-attenuated yellow fever 17D virus is one of the most outstanding human vaccines ever developed. It induces efficacious immune responses at a low production cost with a well-established manufacture process. These advantages make the YF17D virus attractive as a vector for the development of new vaccines. At the beginning of vector development, YF17D was genetically manipulated to express other flavivirus prM and E proteins, components of the viral envelope. While these 17D recombinants are based on the substitution of equivalent YF17D genes, other antigens from unrelated pathogens have also been successfully expressed and delivered by recombinant YF17D viruses employing alternative strategies for genetic manipulation of the YF17D genome. Herein, we discuss these strategies in terms of possibilities of single epitope or larger sequence expression and the main properties of these replication-competent viral platforms.
    Preview · Article · Feb 2014 · Human Vaccines & Immunotherapeutics
Show more